Ideaya biosciences announces us fda ind-clearance for ide849, a potential first-in-class dll3 top1 adc, for a phase 1 study in solid tumors

Targeting to evaluate ide849 (shr-4849) in sclc, nets, and other dll3-upregulated solid tumors, and in combination with ide161/parg to potentially enhance durability targeting to present clinical data of over 40 sclc patients, including the dose escalation and expansion, from partner hengrui at medical conference in q3 2025 south san francisco, calif. , may 6, 2025 /prnewswire/ -- ideaya biosciences, inc. (nasdaq: idya), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced the clearance of an investigational new drug (ind) application with the u.s. food and drug administration (fda) for the initiation of a phase 1 clinical trial to evaluate ide849 (shr-4849), a potential first-in-class delta-like ligand 3 (dll3)-targeting topo-i-payload antibody drug conjugate (adc) program, in solid tumors.
TOP Ratings Summary
TOP Quant Ranking